Suppr超能文献

后Tenon囊下注射曲安奈德治疗葡萄膜炎。

Posterior sub-Tenon's triamcinolone injections in the treatment of uveitis.

作者信息

Tanner V, Kanski J J, Frith P A

机构信息

Oxford Eye Hospital, UK.

出版信息

Eye (Lond). 1998;12 ( Pt 4):679-85. doi: 10.1038/eye.1998.168.

Abstract

PURPOSE

This is the first study reported in the United Kingdom to investigate the efficacy and safety of posterior, sub-Tenon's triamcinolone acetonide injections in the treatment of posterior and intermediate uveitis.

METHODS

Twenty-eight posterior sub-Tenon's triamcinolone injections (40 mg) were given and the results analysed with a 6 month prospective follow-up in 13 cases.

RESULTS

At 6 weeks follow-up, objective improvement in visual acuity occurred in 25 eyes (p < 0.05). Vitreous cellular activity was diminished in 21 eyes (p < 0.05). In most cases improvement was observed within 2 weeks of injection. No patient required repeat triamcinolone injection within 3 months and all patients previously treated with systemic immunosuppression were able to decrease or discontinue this treatment. Complications included transient elevation of intraocular pressure in 4 patients and persistent mild ptosis in 2 patients.

CONCLUSIONS

We have demonstrated that posterior sub-Tenon's triamcinolone injection significantly decreases cystoid macular oedema, with a corresponding increase in visual acuity, in patients with posterior uveitis. Systemic immunosuppression may be reduced or discontinued with the avoidance of associated systemic side effects, and the technique has a high level of patient acceptability.

摘要

目的

这是英国报道的第一项研究,旨在调查后Tenon囊下注射曲安奈德治疗后葡萄膜炎和中间葡萄膜炎的疗效和安全性。

方法

进行了28次后Tenon囊下曲安奈德注射(40毫克),并对13例患者进行了为期6个月的前瞻性随访,分析结果。

结果

在6周的随访中,25只眼的视力有客观改善(p < 0.05)。21只眼的玻璃体细胞活性降低(p < 0.05)。在大多数情况下,注射后2周内观察到改善。3个月内无患者需要重复注射曲安奈德,所有先前接受全身免疫抑制治疗的患者都能够减少或停止这种治疗。并发症包括4例患者眼压短暂升高和2例患者持续性轻度上睑下垂。

结论

我们已经证明,后Tenon囊下注射曲安奈德可显著降低后葡萄膜炎患者的黄斑囊样水肿,并相应提高视力。可减少或停止全身免疫抑制,避免相关的全身副作用,且该技术具有较高的患者接受度。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验